NM23H1

Sodium valproate inhibits MDA-MB-231 breast cancer cell migration by upregulating NM23H1 expression

G. - F. Li, Qian, T. - L., Li, G. - S., Yang, C. - X., Qin, M., Huang, J., Sun, M., and Han, Y. - Q., Sodium valproate inhibits MDA-MB-231 breast cancer cell migration by upregulating NM23H1 expression, vol. 11, pp. 77-86, 2012.

Breast cancer is a common cancer in women, with a highly variable course, from inoffensive to lethal. To find a more effective strategy for its treatment, sodium valproate has been tested as an anti-cancer drug; it is the only clinically available histone deacetylase inhibitor. However, data about the effects of sodium valproate on breast cancer are insufficient in both animals and humans; studies have yielded conflicting conclusions. In particular, little is known about the association between expression of the metastasis suppressor Nm23H1 gene and breast cancer.

Subscribe to NM23H1